Top and Current
Source: (remove) : Amit Hazan
RSSJSONXMLCSV
Top and Current
Source: (remove) : Amit Hazan
RSSJSONXMLCSV
Wed, November 30, 2022
Wed, November 23, 2022
Thu, November 3, 2022
Wed, September 7, 2022
Tue, August 16, 2022
Mon, August 8, 2022
Wed, August 3, 2022
Mon, July 25, 2022
Thu, July 14, 2022
Tue, May 31, 2022
Wed, April 13, 2022
Mon, April 4, 2022
Mon, March 21, 2022
Fri, December 3, 2021
Tue, August 3, 2021
Thu, July 1, 2021
Mon, March 8, 2021
Wed, December 2, 2020
Mon, June 1, 2020
Wed, April 1, 2020
Thu, February 13, 2020
Wed, January 2, 2019
Tue, November 13, 2018
Thu, November 1, 2018
Fri, August 17, 2018
Wed, August 8, 2018
Tue, July 31, 2018
Mon, April 30, 2018
Tue, April 24, 2018
Tue, April 10, 2018
Wed, February 28, 2018
Tue, February 27, 2018
Tue, February 6, 2018
Tue, January 30, 2018
Thu, October 19, 2017
Thu, August 17, 2017
Thu, November 12, 2015
Tue, March 24, 2015

Amit Hazan Maintained (BVS) at Hold with Decreased Target to $2.5 on, Nov 30th, 2022


Published on 2024-10-28 00:22:29 - WOPRAI, Amit Hazan
  Print publication without navigation


Amit Hazan of Goldman Sachs, Maintained "Bioventus Inc." (BVS) at Hold with Decreased Target from $13 to $2.5 on, Nov 30th, 2022.

Amit has made no other calls on BVS in the last 4 months.



There are 4 other peers that have a rating on BVS. Out of the 4 peers that are also analyzing BVS, 2 agree with Amit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Alexander Nowak of "Craig-Hallum" Downgraded from Strong Buy to Hold on, Tuesday, November 22nd, 2022
  • Kyle Rose of "Canaccord Genuity" Downgraded from Strong Buy to Hold on, Wednesday, November 9th, 2022


These are the ratings of the 2 analyists that currently disagree with Amit


  • Drew Ranieri of "Morgan Stanley" Maintained at Buy with Decreased Target to $5 on, Thursday, November 10th, 2022
  • Robbie Marcus of "JP Morgan" Downgraded from Buy to Sell on, Wednesday, November 9th, 2022